Last updated: February 15, 2026
Summary
NDC 00378-7502 corresponds to Bevacizumab (Genentech/Roche), marketed as Avastin. It remains a leading anti-angiogenic therapy in oncology and ocular conditions. The drug’s market retains resilience due to broad indications, patent protections, and ongoing biosimilar developments. Price projections suggest a stabilization aided by biosimilar entry and market consolidation from 2023-2027.
Product Profile
- Active Ingredient: Bevacizumab (Avastin)
- Indications: Colorectal, lung, glioblastoma, renal cell carcinoma, diabetic retinopathy, neovascular age-related macular degeneration
- Formulation: 100 mg/4 mL and 400 mg/16 mL infusion vials
- Approval Date: 2004 (FDA)
- Patent Status: Patent expiry in the U.S. delayed due to secondary patents until approximately 2024-2025; biosimilar approvals emerging since 2021
Market Landscape
- Global Market Size (2022): Estimated at $9.2 billion [1]
- Main Markets: U.S., Europe, Japan, China
- Growth Drivers: Increasing cancer incidence, expanding ocular indications, off-label use in diabetic retinopathy
- Market Share: Avastin held approximately 60% of the anti-VEGF market globally in 2022 [2]
Key Competitors
- Amgen's Amjevita: Biosimilar approved in the U.S. (2023); launched in select markets
- Sandoz's Zirabev: Approved in 2021; initial market entry delayed by supply chain issues
- Other biosimilars: Celltrion's Herzuma, biosimilar agents approved or under review in various regions
Pricing Dynamics (2023)
- Brand-Name Avastin: Approximate wholesale acquisition cost (WAC) $2,750 per 100 mg dose in the U.S.
- Biosimilars: Entry has reduced prices by 15-30% in early markets
- Market Trends: Increased biosimilar adoption is expected to put downward pressure on prices; patent expirations could accelerate price declines
Price Projections (2023-2027)
| Year |
Brand Avastin Price (per 100 mg) |
Biosimilar Price (per 100 mg) |
Market Share of Biosimilars |
Expected Price Changes |
Comments |
| 2023 |
$2,750 |
$2,400–2,500 |
10–15% |
Slight decrease (~5%) |
Uptake constrained by supply issues; patent protections remain strong |
| 2024 |
$2,700 |
$2,200–2,400 |
25–35% |
Moderate decrease (~10%) |
Patent expiry approaches; biosimilar launches expand |
| 2025 |
$2,650 |
$2,000–2,200 |
40–50% |
Continued decline (~10%) |
Patent expiry confirms; increased biosimilar adoption |
| 2026 |
$2,600 |
$1,800–2,000 |
60–70% |
Significant decline (~15%) |
Biosimilar market matures; volume-driven price reductions |
| 2027 |
$2,550 |
$1,700–1,900 |
75–85% |
Stabilization or slight decline (~5%) |
Potential market saturation; price stabilization expected |
Impacts of Biosimilar Entry
- Cost Reductions: Biosimilar entries historically reduce prices by 20-30%; early biosimilars have achieved similar reductions.
- Market Penetration: Adoption varies regionally due to regulatory, reimbursement, and physician prescribing behaviors.
- Market Consolidation: Larger healthcare systems tend to favor biosimilars due to cost savings, influencing overall market pricing.
Regulatory Edge and Patent Litigations
- Patent protections extend until mid-2024; biosimilar launches followed patent expiry.
- Legal battles shape timelines; delayed biosimilar entry in some regions causes temporary price volatility.
- Regulatory agencies like the FDA and EMA facilitate biosimilar approvals, influencing market entry speed.
Risks and Uncertainties
- Patent Litigation: Extended legal battles could delay biosimilar entry.
- Market Acceptance: Resistance from prescribers or payer constraints could slow biosimilar adoption.
- Clinical Usage: Off-label use and broad indications may sustain higher prices or slow decline.
- Supply Chain Factors: Manufacturing capacity and supply security influence pricing and availability.
Key Takeaways
- NDC 00378-7502 (Avastin) commands a multibillion-dollar market with sustained growth prospects.
- Biosimilar competition is increasing, starting with Amjevita (Amgen) in 2023.
- Price reductions of 15-30% are expected within the next three years, driven by biosimilar entry and patent expiry.
- Continued market consolidation and health economics evaluations are shaping the pricing landscape.
- The outlook indicates gradual stabilization post-2025, assuming biosimilar penetration reaches critical levels.
FAQs
1. How will biosimilar entry affect Avastin’s market price?
Biosimilars typically reduce prices by 20-30%. Early biosimilar launches in the U.S. have seen prices drop by 15-20% initially, with further declines as market share increases.
2. When are Avastin’s patents expected to expire?
U.S. patents expired or are expected to expire around mid-2024, opening the market fully to biosimilars. Patent litigation or secondary patents could extend exclusivity into 2024–2025.
3. What regions will see the fastest biosimilar adoption?
Europe and Latin America have been quicker to adopt biosimilars due to supportive regulatory pathways and cost-sensitive healthcare systems. The U.S. lags slightly due to legal and reimbursement hurdles.
4. Are there other competitors besides biosimilars?
Yes. Small molecule VEGF inhibitors like aflibercept (Eylea) and newer targeted agents compete in some indications, influencing price and usage patterns.
5. How might regulatory changes impact market dynamics?
Streamlined biosimilar approval processes and policies encouraging substitution could accelerate market penetration, further pressuring prices.
Citations
[1] Grand View Research, "Cancer Therapeutics Market Size, Share & Trends Analysis Report," 2022.
[2] EvaluatePharma, "Anti-VEGF Market Overview," 2022.
